Icon’s (ICLR) Market Perform Rating Reiterated at Leerink Partners

Leerink Partners reiterated their market perform rating on shares of Icon (NASDAQ:ICLR) in a research report sent to investors on Thursday, Marketbeat Ratings reports. They currently have a $105.00 price objective on the medical research company’s stock.

A number of other brokerages have also recently issued reports on ICLR. Weiss Ratings reiterated a “hold (c)” rating on shares of Icon in a research report on Monday, December 29th. UBS Group set a $220.00 price objective on shares of Icon in a report on Friday, October 24th. Robert W. Baird set a $217.00 target price on Icon in a report on Friday, January 9th. Bank of America lowered Icon from a “buy” rating to a “neutral” rating and set a $195.00 price target on the stock. in a research report on Monday, December 15th. Finally, Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $173.40.

Icon Stock Up 16.1%

NASDAQ ICLR opened at $93.00 on Thursday. Icon has a 1-year low of $66.57 and a 1-year high of $211.00. The company has a market capitalization of $7.51 billion, a price-to-earnings ratio of 12.58, a PEG ratio of 1.95 and a beta of 1.27. The stock’s 50 day moving average is $175.93 and its two-hundred day moving average is $174.87. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Institutional Trading of Icon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC grew its holdings in Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after purchasing an additional 56 shares during the period. Geneos Wealth Management Inc. boosted its position in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares in the last quarter. Spire Wealth Management grew its holdings in shares of Icon by 10.1% in the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after buying an additional 62 shares during the period. New Wave Wealth Advisors LLC increased its position in shares of Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after buying an additional 72 shares in the last quarter. Finally, Signaturefd LLC raised its stake in Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after buying an additional 72 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Some analyst support remains — Leerink Partners reaffirmed a “market perform” rating and a $105 price target, providing a floor for some investors. Leerink note
• Neutral Sentiment: ICON issued a timing update saying it is delaying release of Q4 and full‑year 2025 earnings while the internal investigation continues — the announcement is procedural but keeps uncertainty elevated until results are filed. Company update
• Negative Sentiment: Multiple law firms have opened securities‑fraud investigations and are soliciting shareholders after ICON disclosed possible revenue‑recognition issues; that legal overhang amplifies downside risk and potential remediation costs. Glancy announcement
• Negative Sentiment: Market reaction has already been severe: the initial accounting‑probe disclosure produced a large intraday share collapse and prompted additional plaintiff firms (Hagens Berman, Rosen, Block & Leviton, Frank R. Cruz, Ademi, Holzer & Holzer, Johnson Fistel, etc.) to launch or publicize investigations, increasing litigation risk and potential settlement exposure. Hagens Berman note
• Negative Sentiment: ICON pulled its 2025 outlook amid the probe and signaled potential revenue‑recognition restatements, which elevates execution risk and clouds near‑term earnings visibility — a key reason analysts and investors moved to cut exposure. Seeking Alpha

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.